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Abstract 
Problem: Cigarette smoking is the most important risk factor of transitional cell 
carcinoma of the urinary bladder. The effect of the glutathione S-transferases M1 
(GSTM1) and M3 (GSTM3) on the influence of this risk factor was investigated. 
Methods: A total of 293 bladder cancer patients from Dortmund and Wittenberg as 
well  as  176  surgical  patients  without  any  malignancy  from  Dortmund  were 
genotyped for GSTM1 und GSTM3 according to standard PCR/RFLP methods. 
Smoking habits were also qualified by a standardized interview. 
Results: The percentage of GSTM1 negative cases was 63 % in the entire bladder 
cancer  patient  group  compared  to  50  %  in  the  control  group.  GSTM3*A/*A 
genotype  was  76  %  in  the  entire  group  of  bladder  cancer  cases  and  74  %  in 
controls. Smokers and ex-smokers were overrepresented in the bladder cancer 
patient group. A significant association between smoking status and GSTM1 or 
GSTM3 genotype could not be revealed. 
Conclusion: The elevated percentage of GSTM1 negative bladder cancer cases 
shows  the  important  effect  of  this  polymorphic  enzyme  on  the  development  of 
bladder cancer. In contrast to some other studies, an influence of GSTM1 on the 
risk due to cigarette smoking could not be observed. 
 
Key Words: Bladder  cancer,  glutathione  S-transferase  M1,  glutathione  S-
transferase M3, smoking 
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1 Introduction 
In 1998, a total of 10,546 bladder cancer cases in Germany among men and 5,190 
cases  among  women  were  newly  diagnosed  (ARBEITSGEMEINSCHAFT 
BEVÖLKERUNGSBEZOGENER KREBSREGISTER IN DEUTSCHLAND, 2002). 
 
The transitional cell carcinoma (TCC; synonym: urothelial cancer) of the urinary 
bladder is a typical example of chemical induced carcinogenesis. For example, 
aromatic  amines  and  soluble  azo  dyes  which  can  be  released  in  the  human 
organism could be revealed as carcinogens in many former studies (MYSLAK UND 
BOLT, 1988; VINEIS, 1994; GOLKA ET AL., 2004). 
 
In 1993, BELL ET AL. showed that the majority of patients suffering from transitional 
cell carcinoma of the bladder who smoked a certain amount of cigarettes were 
lacking the gene for glutathione S-transferase M1 (GSTM1). A significantly higher 
incidence  of  the  homozygous  deletion  of  the  GSTM1  genotype  (0/0)  was  also 
found in bladder cancer patients from Dortmund, a former area of former coal, iron 
and steel industries (KEMPKES ET AL., 1996). 
 
This study was conducted to investigate a connection between the smoking status 
and the genotype of two polymorphic glutathione S-transferases M1 and M3 in 
bladder  cancer  patients  from  industrial  areas  and  to  send  the  results  to  the 
International  Collaborative  Study  on  Genetic  Susceptibility  to  Environmental 
Carcinogens  (GSEC;  principal  investigators:  Prof.  Vineis,  Turino;  Dr.  Taioli, 
Milano) for further analyses in a pooled study. 
 
1.1 The superfamiliy of glutathione S-transferases 
Whereas  cytochrome  P450  monooxygenases  are  enzymes  responsible  for  the 
primary oxidation of xenobiotics (“phase I metabolism”), glutathione S-transferases 
(GSTs)  are  a  superfamily  of  enzymes  involved  in  conjugation  (“phase  II 
metabolism”). GSTs seem to have two major functions. First of all, they facilitate 
the conjugation of phase I products with the endogenous tripeptide glutathione, 
which  acts  as  an  essential  cofactor  of  glutathione  S-transferase  activity 
(FJELLSTEDT ET AL., 1973; HABIG ET AL., 1974; MANNERVIK AND DANIELSON, 1988).   3 
Another function of the GSTs is the non-catalytic intracellular transport of non-
polar molecules (e.g., heme, bilirubin, bile acids) in the liver (ISHIGAKI ET AL., 1989). 
 
Conjugation  reactions  facilitate  the  detoxification  of  electrophilic  substances 
(CHASSEAUD, 1979). Electrophilic substances react with the nucleophilic SH-group 
of the glutathione-cysteinyl residue, resulting in covalent binding to the glutathione 
molecule. In the next metabolic step, the GSH-conjugates are cleaved by gamma-
glutamyl-transpeptidases  and  dipeptidases,  followed  by  acetylation  to  facilitate 
renal excretion. 
Important  carcinogenic  substrates  of  GSTs  include  polycyclic  aromatic 
hydrocarbons (pah; e.g., benz(a)pyrene (ROBERTSON  ET  AL., 1986), aflatoxin B1 
(RANEY ET AL., 1992) or styrene oxide (PACIFICI ET AL., 1987). 
1.1.2 Genetic polymorphisms of GSTM1 and GSTM3 
The  genes  coding  for  GST  enzymes  are  arranged  in  clusters  in  the  human 
genome, with each cluster containing several highly homologous genes. The class 
µ gene cluster is found at gene locus 1p13 and consists of 5 genes (CANTLAY ET 
AL., 1994). Most authors concluded that about 50% of the Caucasian population 
lack the gene of glutathione S-transferase M1 (e.g., BROCKMÖLLER ET AL., 1994).  
 
In addition, a further polymorphic site has been described in the GSTM1 gene – a 
single C￿G nucleotide substitution in exon 7 leading to an amino acid change, 
resulting  in  the  existence  of  two  variants  of  the  active  allele,  GSTM1*A  and 
GSTM1*B. Although these enzymes have different isoelectric points (6.1, 5.8, and 
5.5, respectively), their specific activities towards typical substrates seem to be 
only marginally different (HAYES ET AL., 1989; WIDERSTEN ET AL., 1991). 
 
In the GSTM3 gene, a small deletion of 3 bp in intron 6, detected by a PCR-RFLP 
assay with MnlI, has been reported (INSKIP ET AL., 1995). Although not within the 
encoding  sequence,  it  appears  to  influence  enzyme  expression  by  creating  a 
recognition motif for the versatile transcription factor YY1 in the GSTM3*B allele 
(INSKIP ET AL., 1995; YENGI ET AL., 1996). The variant allele GSTM3*B additionally 
appears to be in linkage disequilibrium with GSTM1*A (INSKIP ET AL., 1995). The 
presence of this GSTM3 allele has been associated with both increased risk for   4 
certain types of cancer (SCHNAKENBERG ET AL., 2000; LOKTIONOV ET AL., 2001), as 
well as a protective effect for others (YENGI ET AL., 1996).  
 
 
Figure  1:  Glutathione  S-transferase  µ  gene  cluster  with  the  alleles  of  the 
polymorphic 
                GSTM1 und GSTM3 genes (from BROCKMÖLLER ET AL., 2001) 
 
1.2 Transitional cell carcinoma  
Most studies have shown an association between the GSTM1 negative genotype 
and an increased risk of bladder cancer (ENGEL ET AL., 2002). 
In contrast to studies concerning the GSTM1 genotype, only a few studies are 
available which investigate an impact of the GSTM3 genotype on the development 
of certain types of cancer. 
 
In Germany, SCHNAKENBERG ET AL. (2000) investigated 146 patients suffering from 
bladder cancer as well as 206 healthy controls. The GSTM3*A/*A genotype was 
found  in  171  of  206  controls  (83.0  %),  but  only  in  99  of  146  bladder  cancer 
patients (67.8 %). The mutation of the GSTM3 gene in intron 6 has been reported 
to be associated with a significantly elevated bladder cancer risk (OR 2.31, 95% CI 
1.79-2.82). 
1.2.1 Smoking and bladder cancer 
The  by  far  most  important  non-occupational  risk  factor  for  bladder  cancer  is 
smoking. It has been estimated (IARC, 2004) that in some areas up to 50 % of   5 
bladder  cancer  cases  in  men  and  up  to  25  %  in  women  are  due  to  tobacco 
smoking. For men who are smoking cigarettes the bladder cancer risk is highest in 
Northern Italy and Spain and lowest in several eastern and northern European 
countries (NEGRI  AND LA VECCHIA, 2001). A possible explanation is the different 
treatment of raw tobacco in different countries. CLAVEL ET AL. (1989) have reported 
that “black”, i.e. air-cured tobacco, is a stronger risk factor for bladder cancer than 
“blond“,  i.e.  flue-cured  tobacco.  In  South  East  Europe,  “black”  tobacco  is 
commonly preferred by smokers. 
To date, some 4,000 compounds in tobacco smoke, thereof 69 carcinogens, have 
been identified (IARC, 2004). Very important in regard to the causes of bladder 
cancer in humans are polycyclic aromatic hydrocarbons, different aromatic amines 
which  are  proven  carcinogens  in  humans  like  β-naphthylamine  and 
4-aminodiphenyl  as  well  as  nitrosamines.  The  concentrations  of  each  of  these 
compounds  in  tobacco  smoke  is,  amongst  others,  dependent  on  the  type  of 
tobacco used, drying and processing. 
1.2.2 Smoking, GSTM1 genotype and bladder cancer 
Glutathione S-transferases are important xenobiotic metabolizing enzymes which 
are  involved  in  detoxification  and  elimination  of  important  xenobiotics  like 
polycyclic aromatic hydrocarbons (pah) or aromatic amines. These substances are 
also contained in tobacco smoke. The question raises whether these substances 
might  be  a  risk  factor  for  bladder  cancer  only  for  those  who  have  a  GSTM1 
negative genotype and a smoking history. In other words, the question raises if the 
GSTM1 negative genotype is generally a risk factor for bladder cancer or a risk 
factor only for those subjects with a very special history of exposure to particular 
combustion products from occupational and/or non-occupational sources.  
 
 
2 Materials und Methods 
2.1 Investigated subjects 
In  the  present  study,  patients  from  two  different  urological  departments  were 
investigated in the time period from 1994 to 2000. Altogether, 293 bladder cancer 
patients and 176 patients without any known malignancy were investigated. 
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The bladder cancer patients were from the department of urology of the Klinikum 
Dortmund (transitional cell carcinoma patients (TCC Ca Do) n=83) and from the 
department  of  urology  of  the  Paul-Gerhardt-Stiftung,  Lutherstadt  Wittenberg 
(transitional  cell  carcinoma  patients  Wittenberg  (TCC  Ca  Witt)  n=210).  The 
patients of the control group were from the department of surgery of the Klinikum 
Dormund (control patients Dortmund (Controls Surg Do) n=176). 
 
Demographic data (age, weight, gender, date of birth) and data from the medical 
history, especially those possibly relevant as risk factors for bladder cancer like 
occupational exposure to bladder carcinogenic substances and information on the 
smoking habits were collected (see dissertation Schmidt). 
 
In  all  three  groups,  the  portions  of  the  GSTM1  and  GSTM3  genotypes  were 
investigated in the subgroups of smokers, ex-smokers and non-smokers. A person 
who reported of smoking a certain amount of cigarettes per day at the time of 
completing the questionnaire was defined as a smoker. Persons reporting not to 
smoke any more were classified as ex-smokers. Non smokers were persons who 
reported to have never smoked.  
 
2.2 Statistic analysis 
Differences between subgroups were checked using the p-values of the respective 
χ²  test  of  homogeneity.  Furthermore  odds  ratios  and  confidence  limits  were 
calculated. Note, that ORtotal and CItotal refer to the odds ratio and the confidence 
interval of the total case group (cases of Dortmund and Wittenberg considered 
jointly), ORDo and CIDo refer to the odds ratio and the confidence interval of the 
Dortmund cases and controls and ORWitt and CIWitt refer to the odds ratio and the 
confidence  interval  of  the  Wittenberg  cases  with  the  cases  of  Dortmund  as 
controls. The latter results have to be considered with caution due to potential 
differences between these two groups. 
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3 Results 
3.1 Description and comparison of the investigated groups 
In  this  study,  293  patients  with  a  histologically  ascertained  transitional  cell 
carcinoma  of  the  urinary  bladder  as  well  as  176  surgical  patients  without  any 
known malignancy have been investigated. 
 
The majority of cases of the bladder cancer patients from Dortmund (51 %) as well 
as from Wittenberg (53 %) were older than 65 years. The observed differences 
were not significant (χ
2 = 8.3577, p = 0.21). 
 
Table 1: Age distributions in the investigated groups from Dortmund (controls) and  
      Wittenberg und Dortmund (bladder cancer patients) 
Age (years)  < 58  59 – 65  66 – 72    > 72  Total 
Group           
Controls Surg Do  57 (32%)  47 (27%)  36 (21%)     36 (21%)  176 
TCC Ca Witt  50 (24%)  50 (24%)  56 (27%)  54 (26%)  210 
TCC Ca Do  18 (22%)  23 (28%)  17 (21%)  25 (30%)  83 
TTC Ca Witt + 
TCC Ca Do 
68 (23%)  73 (25%)  73 (25%)  79 (27%)  293 
Total  125 (27%)  120 (27%)  109 (23%)  115 (25%)  469 
 
Gender  
Regarding  the  gender,  noticeable  differences  could  be  observed  between  the 
investigated groups (χ
2 = 53.2392, p < 0.0001; ORtotal = 4.9, CItotal = [3.1 – 7.7]). 
Whilst  in  both  bladder  cancer  groups  males  were  clearly  overrepresented 
(Wittenberg: 87 %, Dortmund: 86 %), there was only a slightly elevated portion of 
males in the control group (56 %).  
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Table 2: Gender in the investigated groups 
Gender 
 
Male  Female  Total 
Group       
Controls Surg Do  99 (56%)  77 (44%)  176 
TCC Ca Witt  182 (87%)  28 (13%)  210 
TCC Ca Do  71 (86%)  12 (15%)  83 
TCC Ca Witt + 
TCC Ca Do 
253 (86%)  40 (14%)  293 
 
Smoking habits  
All  patients  of  the  three  investigated  groups  were  stratified  for  “smokers“,  “ex-
smokers“  and  “non-smokers”  according  to  the  information  taken  from  the 
questionnaires.  Additionally,  different  parameters  characterizing  smoking  habits 
like the number of pack years, age at the beginning of smoking and duration of 
non-smoking in ex-smokers were investigated. 
 
The smoking habits in the two bladder cancer groups were quite different from that 
in the controls (χ
2 = 20.2769, p = 0.0004). Both, smokers (ORtotal = 2.7, CItotal = [1.5 
– 4.0]; ORWitt = 2.1, CIWitt = [1.2 – 3.6]; ORDo = 3.7, CIDo = [1.7 – 7.6]) and ex-
smokers (ORtotal = 2.3, CItotal = [1.5 – 3.7], ORWitt = 2.6, CIWitt = [1.3 – 5.4]; ORDo = 
2.2, CIDo = [1.4 – 3.7]) showed an elevated risk of bladder cancer.  
In  bladder  cancer  patients  from  Wittenberg,  compared  to  the  bladder  cancer 
patients  from  Dortmund,  the  portion  of  ex-smokers  was  slightly  elevated.  The 
portion of smokers in bladder cancer patients from Dortmund was higher than that 
from Wittenberg. In contrast, in the control group a large portion of non-smokers 
was observed (39 %). Five patients did not provide data on their smoking habits. 
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Table 3: Bladder cancer patients and controls classified for smoking status 
Smoking status  Ex-smoker  Smoker  Non-smoker   Total 
Group         
Controls Surg Do  59 (35%)  46 (27%)  66 (39%)     171 
TCC Ca Witt  94 (45%)  69 (33%)  47 (22%)  210 
TCC Ca Do  33 (40%)  36 (43%)  14 (17%)  83 
TCC Ca Witt + 
TCC Ca Do 
127 (43%)  105 (36%)  61 (21%)  283 
 
Regarding the pack years, significant differences could be observed between the 
investigated groups (χ
2 = 65.4243, p < 0.001). The opposed distribution in the two 
investigated  bladder  cancer  groups  is  striking.  A  total  of  26  %  of  the  bladder 
cancer  patients  from  Wittenberg  reported  0-10  pack  years.  With  increasing 
numbers of pack years, the percentage was decreasing almost arithmetically. Only 
13 % reported on more than 40 pack years. An opposed trend was observed in 
bladder  cancer  patients  from  Dortmund:  2  %  reported  on  0-10  pack  years, 
whereas 49 % reported on more than 40 pack years. 
 
Table 4: Number of pack years reported in the investigated groups 
Pack years  0-10  11-20  21-30  31-40  > 40  Total 
Group             
Controls Surg Do  8 (8%)  7 (7%)  21 (20%)  39 (38%)  29 (28%)  104 
TCC Ca Witt  40 (26%)  35 (23%)  32 (21%)  26 (17%)  20 (13%)  153 
TCC Ca Do  1 (2%)  7 (13%)  9 (17%)  10 (19%)  26 (49%)  53 
TCC Ca Witt + 
TCC Ca Do 
41 (20%)  42 /21%)  41 (20%)  36 (18%)  46 (23%)  203 
 
Patients  from  all  three  groups  who  reported  to  have  smoked  were  also 
investigated for age at beginning of smoking. In all the three groups, a low age at 
starting the smoking career was observed. 
 
The age at the beginning of smoking was quite different in the investigated groups 
(χ
2 = 9.7424,  p = 0.0077).  Only  13 %  of  the  control  group  were  older  than  25   10 
years, in contrast to 33 % of the bladder cancer patients from Wittenberg as well 
as  to  24 %  of  the  bladder  cancer  patients  from  Dortmund.  Thus,  beginning  of 
smoking at an age of < 20 could not be confirmed as a risk factor for bladder 
cancer (ORtotal = 0.3, CItotal = [0.2 – 0.7]) 
 
Table 5: Age at the beginning of smoking 
Age at beginning of smoking  < 20 years old  > 25 years old 
Group     
Controls Surg Do      66 (87%)       10 (13%) 
TCC Ca Witt     79 (67%)       39 (33%) 
TCC Ca Do     31 (76%)       10 (24%) 
TCC Ca Witt + 
TCC Ca Do 
  110 (69%)       49 (31%) 
 
In  another  step,  the  subgroups  of  ex-smokers  were  investigated  for  possible 
differences in the duration of having quitted smoking until the time of interview. No 
significant  differences  were  observed  between  the  investigated  groups 
(χ
2 = 7.2949, p = 0.29). Only 22 % of the bladder cancer patients from Wittenberg 
and  39  %  of  the  bladder  cancer  patients  from  Dortmund  reported  a  period  of 
having quitted smoking ≤ 9 years, the remaining ex-smokers have quitted smoking 
for more than 9 years. 
 
Table 6: Duration of abstinence in years from smoking in ex-smokers in the investigated  
                groups 
Abstinence (years)  0-4  5-9  10-19  < 20  Total 
Group           
Controls Surg Do  10 (17%)  11 (19%)  15 (25%)  23 (39%)  59 
TCC Ca Witt  11 (12%)  9 (10%)  30 (32%)  44 (47)  94 
TCC Ca Do  7 (25%)  4 (14%)  9 (32%)  8 (29%)  28 
TCC Ca Witt + 
TCC Ca Do 
18 (15%)  13 (11%)  39 (32%)  52 (43%)  122 
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Tumor staging und grading 
The extensions of the tumours in patients from Dortmund and Wittenberg were 
remarkably different (χ
2 = 38.5833, p < 0.0001). In bladder cancer patients from 
Wittenberg, tumours staged Ta und T1 (i.e., low invasiveness) were more often 
seen than in patients from Dortmund (76 % vs. 66 %). Furthermore, no patient 
from Wittenberg was staged with T4 (i.e., high invasiveness), in contrast to 5 % of 
the patients from Dortmund. 
 
Table 7: Tumour staging of bladder cancer patients from Dortmund and Wittenberg 
Staging  Ta  T1  T2  T3  T4  Total 
Group             
TCC Ca Witt  74 (36%)  82 (40%)  9 (4%)  42 (20%)  0  207 
TCC Ca Do  20 (27%)  29 (39%)  17 (23%)  5 (7%)  4 (5%)  75 
TCC Ca Witt + 
TCC Ca Do 
94 (33%)  111 (39%)  26 (9%)  47 (17%)  4 (1%)  282 
 
The results regarding the grading of the bladder cancer tumours from Dortmund 
and Wittenberg were close to significance (χ
2 = 6.6159, p = 0.085). In more than 
50 %, bladder cancer cases from Dortmund were graded G2; there was a trend 
for higher gradings in patients from Wittenberg. 
 
Table 8: Grading of bladder cancer patients from Dortmund and Wittenberg 
Grading  G1  G2  G3  G4  Total 
Group           
TCC Ca Witt  56 (27%)  76 (37%)  74 (36%)  1 (1%)  207 
TCC Ca Do  21 (28%)  38 (51%)  16 (21%)  0  75 
TCC Ca Witt + 
TCC Ca Do 
77 (22%)  114 (40%)  90 (32%)  1 (1%)  282 
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3.2 Glutathione S-transferase M1 genotyping 
Distribution of the *A and *B alleles in the investigated groups  
No statistically significant differences in the distribution of the investigated GSTM1 
negative genotype was observed in the bladder cancer groups from Dortmund and 
Wittenberg  (χ
2 = 3.4141,  p = 0.33),  Thus,  the  two  bladder  cancer  groups  were 
combined to one group. 
 
On the basis of the literature, the GSTM1 negative genotype is a genetically based 
risk factor for bladder cancer. This was also confirmed in the present study. A 
remarkable overrepresentation of the GSTM1 negative phenotype was observed 
in the bladder cancer patients group compared to the controls who provided a 
medical history without any malignancy (63 % bladder cancer patients vs. 50 % 
controls).  The  difference  was  statistically  significant  (χ
2 = 11.1412,  p = 0.01). 
Furthermore, the GSTM1*A allele was more frequently observed in the controls 
(31 % in controls vs. 20 % in bladder cancer patients) leading to a lower risk of 
bladder cancer (ORtotal = 0.5, CItotal = [0.3 – 0.8] for GSTM1*A/*A or GSTM1*A/*0) 
whereas the GSTM1*B showed no significant difference (ORtotal = 0.9, CItotal = [0.5 
– 1.5] for GSTM1*B/*B or GSTM1*B/*0). Due to the low numbers of GSTM1*A/*B 
genotypes a reduced risk could not be confirmed significantly (ORtotal = 0.4, CItotal = 
[0.1 – 1.0]) for GSTM1*A/*B. 
 
Table 9: GSTM1 genotype in the investigated groups 




*A/*B  Total 
Group           
Controls Surg Do  88 (50%)  54 (31%)  24 (14%)  10 (6%)  176 
TCC Ca Witt + 
TCC Ca Do 
184 (63%)  58 (20%)  43 (15%)  8 (3%)  293 
 
An  association  between  GSTM1  genotype  and  age  or  gender  was  not  found.  An 
increased  occurrence  of  the  GSTM1  negative  genotype  in  smokers  and  ex-
smokers could not be found (χ
2 = 2.9830, p = 0.81). A total of 67 % in smokers 
and 71 % in non-smokers presented the GSTM1 negative genotype. Furthermore,   13
no relevant association between the GSTM1 genotype and number of pack years, 
age at the beginning of smoking and duration of having quitted smoking in ex-
smokers could be observed. 
 
3.3 Glutathione S-transferase M3 genotype 
Distribution in the investigated groups 
The portion of the investigated GSTM3 genotypes in the investigated groups was 
approximately the same. There was no evidence for the association of a particular 
GSTM3 genotype with bladder cancer. In the wide majority of cases in all three 
investigated  groups,  the  GSTM3*A/*A  genotype  was  detected  (controls 
Dortmund:  74 %,  bladder  cancer  patients  Wittenberg:  75 %,  bladder  cancer 
patients  Dortmund:  78 %).  Only  very  few  patients  presented  the  homozygous 
GSTM3*B/*B genotype (2 % vs. 1 % vs. 1 %) 
GSTM3 genotype and age 
An  association  between  the  GSTM3  genotype  and  age  or  gender  was  not 
observed.  
 
Table 10: GSTM3 genotype in the investigated groups  
GSTM3 genotype  *A/*A  *A/*B  *B/*B  Total 
Group         
Controls Surg Do  130 (74%)  43 (24%)  3 (2%)  176 
TCC Ca Witt  158 (75%)  50 (24%)  2 (1%)  210 
TCC Ca Do  65 (78%)  17 (21%)  1 (1%)  83 
TCC Ca Witt + 
TCC Ca Do 
223 (76%)  67 (23%)  3 (1%)  293 
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Table 11: GSTM3 genotype in dependence of the GSTM1 genotype in bladder cancer 
                   patients from Wittenberg 
GSTM3 genotype  *A/*A  *A/*B  *B/*B  Total 
GSTM1 genotype         
*0/*0  107 (85%)  18 (14%)  1 (1%)  126 
*A/*0 or *A/*A  21 (47%)  23 (51%)  1 (2%)  45 
*B/*0 or*B/*B  27 (79%)  7 (21%)  0  34 
*A/*B  3 (60%)  2 (40%)  0  5 
 
Table 12: GSTM3 genotypes in dependence of the GSTM1 genotypes in controls from 
                   Dortmund 
GSTM3 genotype  *A/*A  *A/*B  *B/*B  Total 
GSTM1 genotype         
*0/*0  78 (87%)  9 (10%)  1 (1%)  88 
*A/*0 or *A/*A  28 (52%)  24 (44%)  2 (4%)  54 
*B/*0 or *B/*B  21 (88%)  3 (13%)  0  24 
*A/*B  3 (30%)  7 (70%)  0  10 
 
Table 13: GSTM3 genotype in dependence of the GSTM1 genotype in bladder cancer 
                   patients from Dortmund 
GSTM3 genotype  *A/*A  *A/*B  *B/*B  Total 
GSTM1 genotype         
*0/*0  48 (83%)  10 (17%)  0  58 
*A/*0 or *A/*A  6 (46%)  6 (46%)  1 (8%)  13 
*B/*0 or *B/*B  9 (100%)  0  0  9 
*A/*B  2 (67%)  1 (33%)  0  3 
 
GSTM3 genotype and smoking 
In bladder cancer patients from Dortmund, 80 % of the smokers as well as 80 % of 
the  ex-smokers  presented  the  GSTM3*A/*A  genotype.  This  genotype  was   15
presented by 71 % of the non-smokers. Relevant differences were not observed 
(χ
2 = 2.1261, p = 0.71). 
 
Combination of GSTM1*A und GSTM3*B 
A combination of the GSTM1*A allele and the GSTM3*B allele was observed in all 
three  investigated  collectives  (bladder  cancer  patients  Dortmund:  χ
2 = 14.4059, 
p = 0.03;  bladder  cancer  cases  Wittenberg:  χ
2 = 27.4385,  p = 0.0001;  controls 
Dortmund:  χ
2 = 37.3806,  p < 0.0001).  An  elevated  portion  of  the  GSTM3*A/*B 
genotype as well as of the GSTM3*B/*B genotype was observed in patients who 




The definite mechanism which influences the development of bladder cancer has 
not been known so far. To date, polycyclic aromatic hydrocarbons (pah) as well as 
different  aromatic  amines  which  are  proven  carcinogens  in  humans  like  2-
naphthylamine and 4-aminobiphenyl (DOLIN ET AL., 1991; JOHANNSSON ET AL., 1997) 
are of particular interest. 
 
In this study, the contribution of tobacco smoking to an elevated bladder cancer 
risk could be confirmed. In bladder cancer patient groups, the portions of smokers 
and ex-smokers were clearly higher than in the control group (OR = 3.7 smokers 
and OR = 2.2 ex-smokers from Dortmund; OR = 2.1 smokers and OR = 2.6 ex-
smokers from Wittenberg). Regarding the valuation of the high percentages of ex-
smokers in the investigated bladder cancer groups (40 % ex-smokers in bladder 
cancer  patients  from  Dortmund  and  45  %  ex-smokers  in  the  bladder  cancer 
patients from Wittenberg compared with 35 % ex-smokers in the control group 
from Dortmund), it must be taken into account that the present study was designed 
as a retrospective study where the patients were surveyed for their smoking habits 
after the diagnosis of bladder cancer was disclosed. Thus, it should be taken into 
account that some patients might have quitted smoking on the occasion of the first 
symptoms of the disease or at the time the diagnosis was disclosed.  
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An opposed trend in the number of reported pack years was observed in bladder 
cancer  patients  from  Dortmund  and  Wittenberg.  Overall  26  %  of  the  bladder 
cancer  patients  from  Wittenberg  reported  on  0-10  pack  years.  With  increasing 
numbers of pack years, the percentage was decreasing almost arithmetically. Only 
13  %  of  the bladder cancer  patients  reported  on  more  than  40 pack  years.  In 
contrast, 2 % of the bladder cancer patients from Dortmund reported on 0-10 pack 
years and as many as 49 % reported on more than 40 pack years. 
 
It should be clearly kept in mind that in the former German Democratic Republic 
selling of cigarettes was restricted. Cigarettes and other tobacco products were 
only available by vouchers. 
 
The observed differences in the smoking habits might be also due to the different 
cigarette brands available in the former German Democratic Republic and in the 
Federal Republic of Germany.  
 
It  should  be  noted  that  the  type  of  tobacco  and  its  processing,  particularly  the 
drying, may affect the load of the tobacco smoke with toxicants to a considerable 
extent. There are some indications which point to a higher bladder cancer risk for 
smokers  having  consumed  “black”,  i.e.  air-cured,  tobaccos  than  for  those  who 
have consumed “blond”, i.e. flue-cured tobaccos (CLAVEL ET AL., 1989). 
 
Cigarettes  in  the  former  German  Democratic  Republic  contained  up  to  2  mg 
nicotine  and  up  to  24  mg  condensate  – almost  twice  as  much as  most of  the 
cigarettes in the Federal Republic of Germany (FINSTERBUSCH, 1997). It must be 
considered that some patients who were prone to suffer a bladder cancer due to 
tobacco  smoking  at  higher  age,  might  have  died  earlier  due  to  other  tobacco-
related diseases. Further studies will be needed to investigate possible differences 
in bladder cancer risks due to cigarette brands, origin of tobacco, processing of 
tobacco and so on.  
 
Some studies revealed bladder cancer risks in persons who had early in their life 
started tobacco smoking (ZEEGERS ET AL., 2002; SADETZKI ET AL., 1999) and put the   17
hypothesis  forward  that  DNA  damage  early  in  the  life  might  be  compensated 
worse. 
 
In  the  present  study,  such  an  association  could  not  be  observed.  The  large 
majority in smokers actually reported on having started tobacco smoking before 
they turned 20 (Dortmund 76 %, Wittenberg 67 %), but this was in line with the 
large  majority  of  the  smokers  in  the  control  group  that  have  also  started  as 
teenagers (87 %). 
 
In  addition,  in  the  present  study  the  impact  of  the  polymorphic  glutathione  S-
transferases GSTM1 und GSTM3 regarding the susceptibility for bladder cancer 
was investigated. 
 
In the present study, the portion of the GSTM1 negative bladder cancer patients 
was  
63  %,  in  contrast  to  only  50  %  in  the  investigated  controls.  The  difference  is 
statistically significant. 
 
BROCKMÖLLER ET AL. (1994) reported an underrepresentation of GSTM1*A carriers 
in GSTM1 positive bladder cancer patients. Only 23.3 % of the bladder cancer 
patients but 33.5 % of the controls presented the GSTM1*A allele. The authors 
assumed that the GSTM1*A allele might provide a protective effect regarding to 
the development of bladder cancer. 
 
The results observed in the present study point to the same direction. In 31 % of 
the  controls,  the  GSTM1*A  allele  was  detected,  whereas  this  allele  was  only 
observed in 20 % of the bladder cancer patients leading to an odds ratio of 0.5. A 
sound explanation why the GSTM1*A allele, but not the GSTM1*B allele, might 
provide  a  protective  effect  regarding  to bladder  cancer  cannot be  given  at  this 
stage. There is no evidence for differences in enzyme activity and/or substrate 
specificy  between  the  proteins  these  two  alleles  code for  (HAYES  ET  AL.,  1989; 
WIDERSTEN  ET  AL.,  1991).  Only  differences  in  the  isoelectric  point  have  been 
observed  in  the  proteins.  Possibly,  differences  in  the  steric  structure  of  the   18 
different  GSTM1  isoenzymes  or  different  binding  affinities  to  substrates  which 
have not been characterized to date might be relevant. 
 
ENGEL  ET  AL.  (2002)  reported  in  a  meta-analysis  of  10  studies,  which  included 
2,149  bladder  cancer  patients  and  1,444  controls,  no  statistically  significant 
association  between  smoking  state,  GSTM1  genotype  and  bladder  cancer. 
Nevertheless, it should be noted that the GSTM1 negative genotype was more 
often observed in smokers. 
 
In the present bladder cancer group from Dortmund, 67 % of the smokers, 73 % of 
the  ex-smokers  and  71  %  of  the  non-smokers  revealed  the  GSTM1  negative 
genotype. The high percentage of the GSTM1 negative genotype in non-smokers 
with bladder cancer is striking. 
 
In GSTM1 negative bladder cancer patients from Wittenberg, patients reporting to 
be  a  smoker  were  slightly  overrepresented  (67 %),  compared  to  ex-smokers 
(58 %) and non-smokers (55 %) (χ
2 = 8.6052, p = 0.2). Particularly the results from 
the  patients  from  Dortmund  confirm  the  assumption  that  the  GSTM1  negative 
genotype is a risk factor for bladder cancer not primarily related to smoking habits. 
Occupational and/or environmental exposures to toxicants must be seriously taken 
into account. 
 
A  relevant  impact  of  the  GSTM3  genotype  was  not  observed  for  any  of  the 
investigated parameters which commonly are used to characterize smoking habits 
like number of pack years, age at beginning of smoking, or duration of having 
quitted smoking in ex-smokers. Thus it can be concluded that the GSTM3 state did 
not  modulate  the  bladder  cancer  risk  in  the  two  investigated  bladder  cancer 
groups. 
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